Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Castrate-resistant prostate cancer with peritoneal metastases treated with docetaxel-based chemotherapy.

Rizk R, Danse E, Aydin S, Tombal B, Machiels JP.

Urol Int. 2014;93(1):49-54. doi: 10.1159/000354396. Epub 2013 Nov 30.

PMID:
24296400
[PubMed - in process]
2.

Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.

Miyake H, Sakai I, Terakawa T, Harada K, Fujisawa M.

Urol Oncol. 2013 Aug;31(6):733-8. doi: 10.1016/j.urolonc.2011.06.006. Epub 2011 Jul 22.

PMID:
21782481
[PubMed - indexed for MEDLINE]
3.

Initial Biopsy Gleason Score as a Predictive Marker for Survival Benefit in Patients with Castration-resistant Prostate Cancer Treated with Docetaxel: Data from the TAX327 Study.

van Soest RJ, de Morrée ES, Shen L, Tannock IF, Eisenberger MA, de Wit R.

Eur Urol. 2013 Aug 11. pii: S0302-2838(13)00828-2. doi: 10.1016/j.eururo.2013.08.007. [Epub ahead of print]

PMID:
23957945
[PubMed - as supplied by publisher]
4.

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).

Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ; Alliance for Clinical Trials in Oncology.

Cancer. 2013 Oct 15;119(20):3636-43. doi: 10.1002/cncr.28285. Epub 2013 Jul 31.

PMID:
23913744
[PubMed - indexed for MEDLINE]
5.

Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.

Heck MM, Thalgott M, Retz M, Wolf P, Maurer T, Nawroth R, Hatzichristodoulou G, Gschwend JE, Kübler H.

BJU Int. 2012 Dec;110(11 Pt B):E635-40. doi: 10.1111/j.1464-410X.2012.11364.x. Epub 2012 Aug 13.

PMID:
22889368
[PubMed - indexed for MEDLINE]
6.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

PMID:
22369348
[PubMed - indexed for MEDLINE]
7.

Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.

Peer A, Gottfried M, Sinibaldi V, Carducci MA, Eisenberger MA, Sella A, Leibowitz-Amit R, Berger R, Keizman D.

Prostate. 2014 Apr;74(4):433-40. doi: 10.1002/pros.22765. Epub 2013 Dec 11.

PMID:
24338986
[PubMed - indexed for MEDLINE]
8.

Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.

Schallier D, Decoster L, Braeckman J, Fontaine C, Degrève J.

Anticancer Res. 2012 Feb;32(2):633-41.

PMID:
22287756
[PubMed - indexed for MEDLINE]
9.

Presentation, treatment, and outcomes of dural metastases in men with metastatic castrate-resistant prostate cancer: a case series.

Lawton A, Sudakoff G, Dezelan LC, Davis N.

J Palliat Med. 2010 Sep;13(9):1125-9. doi: 10.1089/jpm.2009.0416.

PMID:
20836637
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.

PMID:
24321502
[PubMed - in process]
11.

Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old.

Miyake H, Sakai I, Harada K, Muramaki M, Fujisawa M.

Int Urol Nephrol. 2012 Dec;44(6):1697-703. doi: 10.1007/s11255-012-0223-z. Epub 2012 Jun 24.

PMID:
22729777
[PubMed - indexed for MEDLINE]
12.

Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.

Qu YY, Dai B, Kong YY, Ye DW, Yao XD, Zhang SL, Zhang HL, Ma CG, Yang WY.

Asian J Androl. 2013 Jan;15(1):110-5. doi: 10.1038/aja.2012.110. Epub 2012 Nov 12.

PMID:
23147466
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy.

Thomas BM, Smith C, Evans J, Button MR, Kumar S, Palaniappan N, Staffurth J, Tanguay JS, Lester JF.

Med Oncol. 2013 Dec;30(4):719. doi: 10.1007/s12032-013-0719-0. Epub 2013 Sep 12.

PMID:
24026658
[PubMed - in process]
14.

Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.

Pond GR, Armstrong AJ, Wood BA, Leopold L, Galsky MD, Sonpavde G.

BJU Int. 2012 Dec;110(11 Pt B):E461-8. doi: 10.1111/j.1464-410X.2012.11148.x. Epub 2012 Apr 23.

PMID:
22520631
[PubMed - indexed for MEDLINE]
15.

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.

Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, De Gouveia P, Leibowitz-Amit R, Knox JJ, Moore M, Sridhar SS, Joshua AM, Pond GR, Amir E, Tannock IF.

Ann Oncol. 2013 Dec;24(12):2972-7. doi: 10.1093/annonc/mdt397. Epub 2013 Oct 14.

PMID:
24126362
[PubMed - indexed for MEDLINE]
16.

Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.

Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, Winquist E; Canadian Uro-Oncology Group.

Clin Cancer Res. 2011 Sep 1;17(17):5765-73. doi: 10.1158/1078-0432.CCR-11-0859. Epub 2011 Jul 25.

PMID:
21788353
[PubMed - indexed for MEDLINE]
Free Article
17.

Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management.

Pestieau SR, Sugarbaker PH.

Dis Colon Rectum. 2000 Oct;43(10):1341-6; discussion 1347-8.

PMID:
11052509
[PubMed - indexed for MEDLINE]
18.

Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.

Jeske S, Tagawa ST, Olowokure O, Selzer J, Giannakakou P, Nanus DM.

Urol Oncol. 2011 Nov-Dec;29(6):676-81. doi: 10.1016/j.urolonc.2009.12.023. Epub 2010 May 7.

PMID:
20451413
[PubMed - indexed for MEDLINE]
19.

The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer.

Goyal J, Nuhn P, Huang P, Tyagi P, Oh D, Carducci MA, Eisenberger MA, Antonarakis ES.

BJU Int. 2012 Dec;110(11 Pt B):E575-82. doi: 10.1111/j.1464-410X.2012.11286.x. Epub 2012 Jun 15.

PMID:
22702837
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M; VENICE investigators.

Lancet Oncol. 2013 Jul;14(8):760-8. doi: 10.1016/S1470-2045(13)70184-0. Epub 2013 Jun 4.

PMID:
23742877
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk